Climb Bio, Inc. (CLYM)
| Market Cap | 285.68M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -64.20M |
| Shares Out | 67.06M |
| EPS (ttm) | -2.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 258,701 |
| Open | 4.680 |
| Previous Close | 4.650 |
| Day's Range | 4.240 - 4.680 |
| 52-Week Range | 2.350 - 11.550 |
| Beta | -0.38 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2024 |
About CLYM
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware. [Read more]
News
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event
Completes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membranous Nephropathy (pMN) Study with plans to Advance to Late Phase Development in 2...
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
WELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that it will present data at the American Society of Nephrology Kidney Week 2024, which will take place in...
Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19
WELLESLEY, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will present and host investor meetings at William Blair's Transforming Autoimmune Diseases by Ta...
Climb Bio to Host Virtual Investor Event on October 15, 2024
WELLESLEY, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will host a virtual investor day on October 15, 2024. The event will feature members of Climb Bio...
Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.
Name change to "Climb Bio" marks the Company's transition and focus on developing treatments for immune-mediated diseases
Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit
SEATTLE and CAMBRIDGE, United Kingdom, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today members of the management team will participate at the Stifel 2024 Vi...
Eliem Therapeutics Announces Additions to its Leadership Team
Brett Kaplan, M.D. appointed Chief Operating Officer Nishi Rampal, M.D.
Eliem Therapeutics Reports Second Quarter Financial Results
Eliem completed the acquisition of Tenet Medicines and concurrent $120 million private placement Eliem to host an Investor Day later in the year to provide an overview of budoprutug (previously referr...
Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value
Results from Eliem Therapeutics, Inc.'s phase 1b study, using TNT119 for the treatment of patients with membranous nephropathy, expected by the end of 2024. It is expected that the global membranous n...
Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes
SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today that the Company will be included in the Russell 2000® Index and the b...
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephrop...
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have approximately $210 million of cash and cash equivale...
Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself
Eliem Therapeutics Inc.'s stock ELYM, -4.76% soared 21% in premarket trade Thursday, after the biotech, which specializes in therapies for neuronal excitability disorders, said it is exploring its str...
Eliem Therapeutics Announces Plans to Explore Strategic Alternatives
SEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) today announced that it has completed a review of its business, including the status of...
Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights
Presented initial preclinical data from ETX-123, Eliem's lead Kv7 program candidate, demonstrating a promising profile and confirming the proposed mechanism of action on neuronal excitability
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights
Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel opener program
Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition
Company to focus on Kv7.2/3 channel opener program and development of lead candidate, ETX-123
Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference
SEATTLE and CAMBRIDGE, United Kingdom, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuro...
Eliem Therapeutics Reports Third Quarter Financial and Business Highlights
Positioned to initiate ETX-155 Phase 2a trial in major depressive disorder in the first quarter of 2023 with 60-milligram dose
Eliem Therapeutics to Participate at Two Upcoming Investor Conferences
SEATTLE and CAMBRIDGE, United Kingdom, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitabilit...
Eliem Therapeutics Provides Update on Pipeline Progress
Company is positioned to initiate Phase 2a trial in major depressive disorder (MDD) in the first quarter of 2023
Eliem Therapeutics Reports Second Quarter Financial and Business Highlights
Initiated Phase 1 pharmacokinetic trial for ETX-155 with expected results in Q4 2022
Eliem's stock slides 20% after saying it will discontinue development of pain treatment
Shares of Eliem Therapeutics Inc. ELYM, -11.51% tumbled 20.0% in premarket trading on Tuesday after the company said it will discontinue development of its treatment for lumbosacral radicular pain aft...
Eliem Therapeutics Provides ETX-810 Program Update
Phase 2a clinical trial of ETX-810 in lumbosacral radicular pain (LSRP) did not achieve the primary endpoint; ETX-810 program will be discontinued Phase 2a clinical trial of ETX-810 in lumbosacral rad...
Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder
Initiating a Phase 1 pharmacokinetics trial of ETX-155 to enable a Phase 2a trial in MDD planned to commence in first quarter of 2023